特朗普行政令降低大麻管制等级，投资者“卖事实”，大麻股普跌

Core Viewpoint - President Trump's decision to downgrade marijuana from a Schedule I controlled substance to a Schedule III category acknowledges its medical value but does not fully legalize it [1][3] Group 1: Policy Changes - The new executive order allows for the reimbursement of CBD products for patients, including cancer patients, under federal health insurance starting next year [1][4] - This reclassification is seen as a significant step in recognizing the medical benefits of marijuana and reducing its perceived abuse potential [3][6] Group 2: Political Reactions - The decision has sparked division within the Republican Party, with 18 senators and 26 House members expressing opposition to the reclassification [1][5] - Despite internal resistance, the Trump administration is continuing this policy shift, which aligns with previous efforts by the Biden administration [5][6] Group 3: Market Impact - Following the announcement, marijuana stocks experienced a significant decline, with ETFs like CNBS dropping nearly 16% and MSOS falling 15.77% [1] - Analysts suggest that the market reaction reflects a "buy the rumor, sell the news" mentality, as investors took profits after substantial gains prior to the executive order [1]